PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
PTC THERAPEUTICS, INC. (PTCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results – Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 t
How this was made
The 30-second read
Why it matters
The raised revenue guidance reflects accelerating product uptake and pipeline progress, likely supporting a positive re‑rating of the stock.
Market read
The guidance lift provides fresh material for traders to reassess valuation and may trigger buying pressure in the biotech sector.
What to watch
Execution risk on upcoming gene‑therapy BLA submissions and potential regulatory delays could temper upside.
PTC Therapeutics reported third-quarter 2026 total revenues of $357,807 (in thousands), led by Sephience net product revenues of $181.9 million, and increased full-year 2026 total revenue guidance to $1.29 to $1.32 billion.
Revenue growth was led by Sephience, commercial portfolio product revenue increased by over 100%, and the company raised both total revenue and product revenue guidance. The quarter nevertheless included a $51.7 million net loss, $111.0 million of acquired in-process R&D expense, and $536,268 (in thousands) of total debt.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | $357.8M | – | – |
| Net product revenue, three months ended September 30, 2026GAAP | $275.9M | – | – |
| Collaboration and license revenue, three months ended September 30, 2026GAAP | $229K | – | – |
| Royalty revenue, three months ended September 30, 2026GAAP | $81.68M | – | – |
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets, three months ended September 30, 2026GAAP | $23.66M | – | – |
| Amortization of acquired intangible assets, three months ended September 30, 2026GAAP | $12.60M | – | – |
| Research and development, three months ended September 30, 2026GAAP | $105.4M | – | – |
| Research and development, three months ended September 30, 2026non-GAAP | $94.87M | – | – |
| Selling, general and administrative, three months ended September 30, 2026GAAP | $80.08M | – | – |
| Selling, general and administrative, three months ended September 30, 2026non-GAAP | $66.73M | – | – |
| Acquired in-process research and development, three months ended September 30, 2026GAAP | $111M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $332.7M | – | – |
| Income from operations, three months ended September 30, 2026GAAP | $25.11M | – | – |
| Interest expense, net, three months ended September 30, 2026GAAP | −$45.87M | – | – |
| Other (expense) income, net, three months ended September 30, 2026GAAP | −$1.07M | – | – |
| Loss on extinguishment of debt, three months ended September 30, 2026GAAP | −$19.26M | – | – |
| (Loss) income before income tax (expense) benefit, three months ended September 30, 2026GAAP | −$41.09M | – | – |
| Income tax (expense) benefit, three months ended September 30, 2026GAAP | −$10.61M | – | – |
| Net (loss) income attributable to common stockholders, three months ended September 30, 2026GAAP | −$51.69M | – | – |
| Net (loss) income per share, basic, three months ended September 30, 2026GAAP | $(0.62) | – | – |
| Net (loss) income per share, diluted, three months ended September 30, 2026GAAP | $(0.62) | – | – |
| Weighted-average shares outstanding, basic, three months ended September 30, 2026GAAP | 83,476,100 | – | – |
| Weighted-average shares outstanding, diluted, three months ended September 30, 2026GAAP | 83,476,100 | – | – |
| Total revenues, nine months ended September 30, 2026GAAP | $990.9M | – | – |
| Net product revenue, nine months ended September 30, 2026GAAP | $740.3M | – | – |
| Collaboration and license revenue, nine months ended September 30, 2026GAAP | $50.97M | – | – |
| Royalty revenue, nine months ended September 30, 2026GAAP | $199.6M | – | – |
| Research and development, nine months ended September 30, 2026GAAP | $305.4M | – | – |
| Research and development, nine months ended September 30, 2026non-GAAP | $273.2M | – | – |
| Selling, general and administrative, nine months ended September 30, 2026GAAP | $246.9M | – | – |
| Selling, general and administrative, nine months ended September 30, 2026non-GAAP | $208.5M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $771.8M | – | – |
| Income from operations, nine months ended September 30, 2026GAAP | $219.1M | – | – |
| Net (loss) income attributable to common stockholders, nine months ended September 30, 2026GAAP | $28.99M | – | – |
| Net (loss) income per share, basic, nine months ended September 30, 2026GAAP | $0.35 | – | – |
| Net (loss) income per share, diluted, nine months ended September 30, 2026GAAP | $0.34 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Sephience net product revenuesContinued growth in the US and ongoing global expansion; $145 million revenue in the US and $37 million revenue ex-US. | $181.9M | 20% growth compared to the second quarter of 2026 | – |
| Translarna net product revenuesThird-quarter 2026 revenue includes a government purchase order from Russia. | $48.5M | – | – |
| Emflaza net product revenuesNo driver was specified. | $25.1M | – | – |
| Evrysdi royalty revenue to PTCRoche reported year-to-date sales of approximately CHF 1,470 million. | $81.7M | – | – |
Full-year 2026 outlook
- RevenueExpected total revenue of $1.29 to $1.32 billion
- Operating expensesGAAP R&D and SG&A expense guidance of $775 to $815 million
- NoteTotal product revenue guidance of $960 to $990 million
- NoteNon-GAAP R&D and SG&A expense guidance of $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million
What drove it
- Total net product revenue across the commercial portfolio was $275.9 million, representing an over 100% increase compared to $131.0 million for the third quarter of 2025.
- Sephience had over 2,000 active patients worldwide as of September 30, 2026.
- The company acquired ST-920 for $111.0 million upfront, with up to an additional $100.0 million in contingent milestone payments based on US regulatory approvals.
- ST-920 BLA submission is expected to be completed in Q4 2026.
- The global Phase 3 INVEST-HD study is actively enrolling, with target enrollment of approximately 770 early symptomatic patients.
- The vatiquinone PROVE-FA study was initiated in Q3 2026 and will enroll approximately 120 patients ages 7 to 21.
Concerns
- Net loss was $51.7 million for the third quarter of 2026, compared to net income of $15.9 million for the third quarter of 2025.
- The company recorded $111.0 million of acquired in-process research and development expense related to ST-920.
- Interest expense, net was $(45,866) (in thousands) for the third quarter of 2026.
- The Type C meeting to discuss votoplam Phase 2 data and a potential accelerated approval path is now scheduled for Q1 2027 due to FDA scheduling.
- Translarna net product revenues were $48.5 million, compared to $50.7 million for the third quarter of 2025, and included a government purchase order from Russia.
- Emflaza net product revenues were $25.1 million, compared to $35.2 million for the third quarter of 2025.
What to watch
- Completion of the ST-920 BLA submission expected in Q4 2026 and the potential FDA accelerated approval and commercial launch in 2027.
- Sephience growth in the US and international markets following $181.9 million of third-quarter net product revenues.
- The Q1 2027 Type C meeting on votoplam Phase 2 data and the potential accelerated approval path.
- Enrollment progress in the Phase 3 INVEST-HD study and the PROVE-FA study.
- Achievement of the company's stated cash flow breakeven milestone this year.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $2,127,918 (in thousands) at September 30, 2026, compared to $1,945,371 (in thousands) at December 31, 2025.
- Total assets were $3,207,715 (in thousands) at September 30, 2026, compared to $2,898,767 (in thousands) at December 31, 2025.
- Total debt was $536,268 (in thousands) at September 30, 2026, compared to $286,631 (in thousands) at December 31, 2025.
- Total liability for sale of future royalties was $2,305,603 (in thousands) at September 30, 2026, compared to $2,308,366 (in thousands) at December 31, 2025.
- Total liabilities were $3,398,924 (in thousands) at September 30, 2026, compared to $3,104,080 (in thousands) at December 31, 2025.
- Total stockholders' deficit was $(191,209) (in thousands) at September 30, 2026, compared to $(205,313) (in thousands) at December 31, 2025.
- Shares issued and outstanding were 83,535,767 as of September 30, 2026, compared to 81,474,366 as of December 31, 2025.
Analysis
Third-quarter revenue was led by commercial product performance. Total revenues were $357,807 (in thousands), compared with $211,007 (in thousands) in the prior-year quarter, while net product revenue was $275,894 (in thousands), compared with $130,956 (in thousands). The company separately reported total net product and royalty revenue of $357.6 million and commercial-portfolio product revenue of $275.9 million, representing an over 100% increase from $131.0 million.
Sephience was the principal growth engine, with $181.9 million of third-quarter net product revenues and 20% growth compared with the second quarter of 2026. The company reported $145 million of Sephience revenue in the US and $37 million ex-US, alongside over 2,000 active patients worldwide as of September 30, 2026. Royalty revenue was $81,684 (in thousands), compared with $70,793 (in thousands), with the release attributing the $81.7 million payable to PTC to Roche-reported Evrysdi year-to-date sales of approximately CHF 1,470 million. Translarna and Emflaza revenues were below their respective prior-year-quarter figures.
The quarter produced income from operations of $25,114 (in thousands), compared with $3,016 (in thousands), but net loss attributable to common stockholders was $(51,693) (in thousands), versus net income of $15,896 (in thousands). The results included $111,000 (in thousands) of acquired in-process research and development expense for the ST-920 purchase and $(19,263) (in thousands) of loss on extinguishment of debt. GAAP R&D was $105,353 (in thousands), non-GAAP R&D was $94,874 (in thousands), GAAP SG&A was $80,081 (in thousands), and non-GAAP SG&A was $66,733 (in thousands).
PTC ended the period with $2,127,918 (in thousands) in cash, cash equivalents and marketable securities, while total debt was $536,268 (in thousands). The company increased full-year guidance to expected total revenue of $1.29 to $1.32 billion and product revenue of $960 to $990 million. It maintained GAAP R&D and SG&A expense guidance of $775 to $815 million and non-GAAP R&D and SG&A expense guidance of $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million.
Pipeline execution remains central to the outlook. PTC expects to complete the ST-920 BLA submission in Q4 2026, while potential FDA accelerated approval and commercial launch are described as 2027 opportunities. The votoplam Type C meeting was moved to Q1 2027 due to FDA scheduling, INVEST-HD is actively enrolling, and PTC initiated the vatiquinone PROVE-FA study during Q3 2026.
Management, verbatim
We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year.
Matthew B. Klein, M.D., Chief Executive Officer
Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.”
Matthew B. Klein, M.D., Chief Executive Officer
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating cash flow
- Free cash flow
- Capital-return activity, including share repurchases and dividends
- Prior-quarter comparisons for consolidated statement-of-operations metrics other than Sephience
- Prior full-year outlook document needed for formal actual-versus-prior-guidance comparisons
- Tax-rate guidance
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
PTC Therapeutics filed a Form 8‑K reporting Q3 2026 results and updated full‑year guidance, highlighting strong Sephience sales and acquisition of a Fabry disease gene therapy.
Ticker impact
PTC Therapeutics issued guidance raising full‑year 2026 total revenue to $1.29‑$1.32 B and product revenue to $960‑$990 M after reporting Q3 results.
potential upside as investors price in higher revenue outlook
Guidance increase of over $200 M signals robust product performance and a clear path to cash‑flow breakeven, which typically supports price appreciation.
Market effects
Biotech and rare‑disease therapeutics sector may see broader optimism from PTC's raised outlook.
U.S. biotech equities could benefit as investors adjust expectations.
Positive guidance may influence global investors tracking rare‑disease pipelines.
Counterpoint
If the raised guidance is already priced in, the stock could face a short‑term pull‑back on profit‑taking.
Key entities
- companyPTC Therapeutics, Inc.
Biopharma focused on rare‑disease treatments.
